Afficher la couverture 'Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial | Scherpereel, A.' en grand format
/5

0 avis

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial

Archive ouverte

Scherpereel, A. | Mazieres, J. | Greillier, L. | Dô, P. | Bylicki, O. | Monnet, I. | Corre, R. | Audigier-Valette, C. | Locatelli-Sanchez, M. | Molinier, O. | Thiberville, L. | Urban, T. | Ligeza-Poisson, C. | Planchard, D. | Amour, E. | Morin, F. | Moro-Sibilot, D. | Zalcman, G.

Edité par CCSD ; American Society of Clinical Oncology -

International audience. LBA8507The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Consulter en ligne

Suggestions

Du même auteur

LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.

Archive ouverte | Zalcman, G. | CCSD

International audience

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Archive ouverte | Peters, S. | CCSD

International audience

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Archive ouverte | Molinier, O. | CCSD

International audience. Background: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) is currently the standard of care in patients ...

Chargement des enrichissements...